Press releaseGlobe Newswire
Assembly Biosciences
ASMB · NASDAQ
$21.19+$1.03 (+5.11%)TodayMarket closed ·
Prev close $20.16
Latest news
- NewsAvi Kapoor
Crude Oil Edges Higher; US Consumer Sentiment Falls In May
- News
Assembly Biosciences Announces Plans To Expand Clinical Development Of ABI-6250 Into Primary Biliary Cholangitis And Primary Sclerosing Cholangitis
- Press releaseGlobe Newswire
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
- NewsAvi Kapoor
Scholastic Posts Upbeat Q3 Earnings, Joins Firefly Aerospace, Arm Holdings And Other Big Stocks Moving Higher On Friday
- News
Assembly Biosciences Q4 EPS $1.30 Beats $(0.65) Estimate, Sales $42.469M Beat $7.423M Estimate
- NewsVandana Singh
Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes
- Press releaseBusiness Wire
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
- News
Forecasting The Future: 4 Analyst Projections For Assembly Biosciences
- NewsRishabh Mishra
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseBusiness Wire
Syndeio Biosciences Launches to Lead the Emerging Field of Synapse-Targeted Neurotherapeutics
- Press releaseGlobe Newswire
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
- Press releaseGlobe Newswire
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.